$CGEM

Cullinan Therapeutics, Inc. (CGEM): Submission of Matters to a Vote of Security Holders

Cullinan Therapeutics, Inc. (CGEM) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001789972 0001789972 2026-06-16 2026-06-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16,

Original reporting
Published Jun 16, 2026, 9:18 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 16, 2026, 9:22 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$CGEM
Neutral
high confidence
Mentioned
$CGEM
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CGEMNeutralLow
01

Why it matters

The disclosure is governance/administrative: election of two Class III directors, ratification of KPMG LLP as independent auditor for 2026, and approval of the advisory vote on executive compensation.

02

Market read

Standard annual meeting outcomes; no new operating or financial catalyst is disclosed.

03

What to watch

Vote tallies alone rarely move biotech stocks; traders should look for concurrent clinical, financing, or regulatory catalysts not present here.

Relevance 6/10Novelty 2/10Timing: Filed June 16, 2026 (after market)

Background

Form 8-K Item 5.07 reports matters submitted to a vote of security holders at the company’s annual meeting.

Company-level read

Ticker impact

$CGEMNeutralHigh confidence
Context

Cullinan Therapeutics filed an 8-K confirming June 16, 2026 shareholder votes on directors, KPMG ratification, and advisory exec comp.

Expected impact

Limited near-term impact; any reaction likely muted unless investors were focused on governance outcomes.

Evidence & confidence

The filing only reports vote tallies for standard proposals (board election, auditor ratification, say-on-pay) without changes to strategy, capital structure, or financial outlook.

Market effects

Minimal; governance vote outcomes typically do not reset sector expectations.

Minimal; company-specific EDGAR disclosure.

Minimal; no cross-border deal/regulatory action mentioned.

Counterpoint

If investors were concerned about auditor independence or board composition, the vote results could reduce uncertainty, but the filing provides no qualitative change beyond tallies.

Key entities

  • Cullinan Therapeutics, Inc.

    Nasdaq-listed company whose annual meeting voting results are reported in the 8-K.

  • KPMG LLP

    Independent registered accounting firm ratified for the fiscal year ending December 31, 2026.

  • Nadim Ahmed

    Elected Class III director (votes For: 37,519,241; Withheld: 12,116,759; Broker non-votes: 4,126,430).

  • Stephen Webster

    Elected Class III director (votes For: 36,963,086; Withheld: 12,672,914; Broker non-votes: 4,126,430).

Related articles

$CGEMMed

Cullinan Therapeutics, Inc.: Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Cullinan Therapeutics (Nasdaq: CGEM) reported Q2 2026 results and a corporate update. It said CLN-978 multi-dose data are planned for Q3 2026 (RA) and Q4 2026 (SLE), with Phase 2 expansions starting early 2027. CLN-049 Phase 2 in relapsed/refractory AML is planned for Q3 2026. Cash was $356.0M at June 30, 2026; net loss was $53.7M.

$CGEMMed

Cullinan Therapeutics, Inc. (CGEM): Results of Operations and Financial Condition

Cullinan Therapeutics, Inc. (CGEM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cgem-ex99_1.htm EX-99.1 EX-99.1 Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results CLN-978 (CD19 TCE) multi-dose regimen data in RA in Q3 2026 and SLE in Q4 2026; Phase 2 expansion studies to begin early 2027 Velinotamig (B

$CGEMMed

Why is Cullinan Therapeutics stock climbing today? By Investing.com

Cullinan Therapeutics (CGEM) shares rose 2.1% in pre-open after the company said it received constructive FDA feedback from an End-of-Phase 1 meeting for CLN-049. Cullinan plans to start a potentially registrational Phase 2 study in Q3 2026, with dose optimization followed by an expansion cohort, and also plans a Phase 1/2 combo study with venetoclax and azacitidine. Fast Track and Orphan Drug designations apply.

SK Hynix said to mull options for US$3 billion Chongqing plant

SK Hynix is considering options for its Chongqing, China semiconductor packaging and testing facility, including possibly bringing in an investor to accelerate growth. People familiar said a potential stake sale could value the plant at about US$3 billion and SK Hynix may keep a minority stake. Separately, it plans a 54 trillion won (US$38 billion) South Korea expansion for DRAM and NAND.